ストックスクリーナーアプリを入手
199.36
0.71%
1.41
アフターアワーズ：
199.50
0.14
+0.07%
前日終値:
$197.95
開ける：
$198.47
24時間の取引高:
1.15M
Relative Volume:
0.98
時価総額：
$29.43B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
21.39
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
+5.41%
1か月 パフォーマンス:
+15.26%
6か月 パフォーマンス:
+23.46%
1年 パフォーマンス:
+60.26%
1日の値動き範囲:
$196.47
$202.40
1週間の範囲:
$188.30
$202.40
52週間の値動き範囲:
$119.18
$202.41
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
199.36 | 29.22B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
989.87 | 862.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.26 | 533.03B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
207.86 | 358.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
184.54 | 282.04B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
148.16 | 277.11B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 77 Tells Investors - GuruFocus
Biogen Inc. stock (US09062X1037): Q1 milestone payment amid partner C4 Therapeutics earnings - AD HOC NEWS
Biogen Inc stock (US09062X1037): Latest developments and business overview - AD HOC NEWS
Biogen (NASDAQ: APLS) clears HSR waiting period for $41 Apellis tender - Stock Titan
Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen? - Yahoo Finance
Should FDA’s LEQEMBI IQLIK Review Delay Reshape How Biogen (BIIB) Investors View Alzheimer’s Strategy? - simplywall.st
Lecanemab Injection Market Report 2026: Increasing Adoption of Monoclonal Antibody Therapies and Rising Focus on Early Alzheimer's Intervention - GlobeNewswire Inc.
Biogen Inc. stock (US09062X1037): Q1 earnings beat but guidance cut weighs on sentiment - AD HOC NEWS
Biogen to Participate in the Bank of America Securities 2026 Health Care Conference - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy - Benzinga
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy - BioSpace
FDA pushes back weekly Alzheimer's shot decision to Aug. 24 - Stock Titan
Eisai and Biogen Announce FDA Extension for LEQEMBI IQLIK Review for Early Alzheimer's Disease Treatment - Quiver Quantitative
FDA extends review period for Eisai, Biogen Alzheimer’s drug By Investing.com - Investing.com Nigeria
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease - Biogen
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease - GlobeNewswire Inc.
Biogen to acquire Apellis (NASDAQ: APLS) with cash+CVR deal - Stock Titan
Some Investors May Be Willing To Look Past Biogen's (NASDAQ:BIIB) Soft Earnings - Moomoo
Has The Market Overlooked Biogen (BIIB) After A 62% One Year Share Price Jump - simplywall.st
FMR LLC holds 12.8M shares of Biogen (NASDAQ: BIIB) in amended 13G/A - Stock Titan
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. (BIIB) exec exercises RSUs, uses shares for taxes - Stock Titan
Apellis (APLS) revises executive separation plan tied to Biogen merger - Stock Titan
Biogen beats estimates as Alzheimer’s drug gains momentum - MSN
Biogen Inc. (BIIB) tops Q1 earnings and revenue estimates - MSN
BIIB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal - simplywall.st
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Artemis Investment Management LLP Buys Shares of 226,845 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Freedom Broker upgrades Biogen stock rating on Apellis acquisition - Investing.com
Freedom Broker upgrades Biogen stock rating on Apellis acquisition By Investing.com - Investing.com Canada
Citigroup Adjusts Biogen Price Target to $200 From $190 - marketscreener.com
Assessing Biogen (BIIB) Valuation After Strong 1 Year Gains And Mixed Longer Term Returns - simplywall.st
H.C. Wainwright reiterates Biogen stock rating on tau therapy trial - Investing.com
Biogen Inc. (NASDAQ:BIIB) Short Interest Up 15.4% in April - MarketBeat
MSN Money - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Goldman Sachs Adjusts Biogen Price Target to $250 From $238 - marketscreener.com
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings - Benzinga
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim raises Biogen stock price target to $260 on strong Q1 results - Investing.com
Biogen Inc. Stock (US09062X1037): Analyst Rating Changes and Q1 2026 Earnings Preview - AD HOC NEWS
Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
BIIB Forecast, Price Target & Analyst Ratings | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative - simplywall.st
Is Biogen (BIIB) 2.7% Undervalued After Q1 2026? Non-GAAP EPS $3 - GuruFocus
A Look at Biogen Inc (BIIB) After 6.0% Gain -- GF Value $199.82 vs Price $194.38 - GuruFocus
Vanguard Capital Management (NASDAQ: BIIB) reports 10.99M Biogen shares ownership - Stock Titan
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
大文字化:
|
ボリューム (24 時間):